Try our beta test site
2090 studies found for:    melanoma
Show Display Options
Rank Status Study
21 Terminated Temodar and Sutent as Therapy for Melanoma
Condition: Metastatic Malignant Melanoma
Intervention: Drug: Temozolomide and SU11248
22 Completed Clinical and Histological Features of Head and Neck Melanoma
Condition: Melanoma
Intervention: Other: Data collection
23 Recruiting Melanoma Molecular Profiling Analysis
Condition: Melanoma
Intervention: Other: Biospecimen banking
24 Recruiting Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
Conditions: Melanoma and Other Malignant Neoplasms of Skin;   Metastatic Melanoma
Interventions: Drug: Azacitidine;   Drug: Pembrolizumab
25 Completed Illness Related Distress in Women With Clinically Localized Cutaneous Melanoma
Condition: Melanoma
Intervention: Behavioral: questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided
26 Recruiting Radiotherapy & Combi in Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Radiation: Palliative radiotherapy;   Drug: Dabrafenib and trametinib (combination)
27 Completed Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma
Condition: Melanoma
Intervention: Other: Sampling of blood
28 Not yet recruiting Melanoma Image Analysis Algorithm (MIAA) Validation Study
Condition: Malignant Melanoma
Intervention: Device: Melanoma Image Analysis Algorithm (MIAA)
29 Not yet recruiting Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
Condition: Melanoma
Interventions: Drug: Dabrafenib;   Drug: Trametinib;   Drug: Pembrolizumab
30 Active, not recruiting A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma
Condition: High Risk Melanoma
Interventions: Drug: Ipilumimab;   Radiation: Radiation
31 Terminated Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells
Condition: Melanoma
Intervention: Other: EGIR Tape
32 Completed cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project
Condition: Melanoma
Intervention: Other: sequencing
33 Not yet recruiting M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma
Condition: Melanoma
Intervention: Biological: M-Vax- autologous, hapten-modified melanoma vaccine
34 Completed Dendritic Cells (DC) Vaccine for Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: Vaccination;   Procedure: Leukapheresis
35 Completed Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma
Condition: Melanoma
Intervention:
36 Completed Evaluation of a Simulation Training Tool to Identify Lesions Requiring Further Screening for Melanoma
Conditions: Skin Simulation Model;   Mastery Learning Model to Simulation Training for Visual Screening for Melanoma and Skin Biopsy
Intervention: Other: Simulation teaching session
37 Unknown  Vaccine Therapy in Treating Patients With Malignant Melanoma
Condition: Melanoma (Skin)
Intervention: Biological: polyvalent melanoma vaccine
38 Completed GM-CSF as Adjuvant Therapy of Melanoma
Condition: Malignant Melanoma
Intervention: Drug: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
39 Completed Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
Condition: Melanoma
Interventions: Biological: MELITAC 12.1;   Drug: Imiquimod
40 Recruiting Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study
Conditions: Metastatic Melanoma;   Brain Metastases
Intervention: Biological: Melanoma antigens-specific CD8+ T lymphocytes

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.